Oslo, Norway is home to the emerging Oslo Cancer Cluster, a growing cluster with a host of exciting companies targeting the oncology therapeutics and diagnostics marketplace. These companies include, Nordic Nanovector, Lytix BioPharm, Targovax and Ultimovacs.
For further reading please see:
- Lytix Biopharma focuses on immuno-oncology future
- Immunotherapeutics biotech Nordic Nanovector demonstrates progress
The Oslo Cancer Cluster has big ambitions to create a global cluster comprised of world-leading experts in cancer drug development and diagnostics and wishes to attract this competence.
With a brand new innovation centre to be launched in 2015, this is an exciting time for this biotech cluster and the companies in it. Liftstream has taken time to profile the cluster through interviews with the Oslo Cancer Cluster leadership, as well as CEO’s of some of the cluster’s companies.
Location: Oslo, Norway – Europe
Population of Oslo: 634,000
Little known fact: Oslo is the fastest growing city in Europe
|Companies||Research & Development|
Cluster talent score (availability of local leadership experience in biotech) – 4/10
Gender Diversity Score (leadership opportunities for women) – 8.5/10
Cluster Executive Competence – Local talent market is underpopulated, need to bring in talent from outside of Oslo and Norway.